Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, and its commercial alcohol metabolism product, unbuzzd. Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments.
Durkacz also highlighted Quantum BioPharma’s commercial product, unbuzzd, which is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. Looking ahead, he noted the company’s upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients following Phase 1 testing in healthy volunteers.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity.
For more information, visit the company’s newsroom at https://ibn.fm/QNTM and view the full press release at https://ibn.fm/8sLvp.
